In a proclamation issued April 2, 2026, President Donald J. Trump declared that imports of patented pharmaceuticals and active pharmaceutical ingredients (APIs) threaten U.S. national security. The administration will pursue agreements with manufacturers and the Department of Health and Human Services to secure on‑shoring and most‑favoured‑nation pricing. The plan imposes a 100‑percent ad‑valorem duty on listed patented drugs, a 20‑percent duty on products from companies with approved on‑shoring plans (to rise to 100 % in 2030), and lower rates for Japan, the EU, Korea, Switzerland and the United Kingdom. Generic drugs and their ingredients are exempt. Tariffs take effect July 31, 2026, with monitoring and potential adjustments overseen by the Secretary of Commerce and related agencies.
© United States Government – Content from Whitehouse.gov (public domain).
If any third‑party material is included, it is used under the Creative Commons Attribution 3.0 Unported licence (https://creativecommons.org/licenses/by/3.0/
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.